Ozempic: Impact on U.S. Obesity Rate
A recent Gallup poll reveals a decline in the obesity rate among U.S. adults over the past three years, coinciding with a significant increase in the use of GLP-1 weight loss drugs like Ozempic and Wegovy.
The survey highlights that women have a higher obesity rate than men and are more likely to use weight management medications. Additionally, individuals between the ages of 40 and 64 have higher obesity rates and utilize GLP-1 drugs more frequently.
However, despite the decline in obesity rates, the poll also notes a record high in diabetes rates in the United States.
The use of GLP-1 weight loss drugs has risen sharply, contributing to the decline in obesity rates.
Author's summary:
Ozempic contributes to US obesity decline.